 visitante ::
identificación
|
|||||||||||||||
|
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español | |||||||||
| Página principal > Artículos > Artículos publicados > Gut microbiome signatures linked to HIV-1 reservoir size and viremia control |
(Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Universitat de Vic - Universitat Central de Catalunya) (Institut Hospital del Mar d'Investigacions Mèdiques) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Universitat Autònoma de Barcelona) (CIBERINFEC, Madrid, Spain) (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institució Catalana de Recerca i Estudis Avançats) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
| Fecha: | 2022 |
| Resumen: | The potential role of the gut microbiome as a predictor of immune-mediated HIV-1 control in the absence of antiretroviral therapy (ART) is still unknown. In the BCN02 clinical trial, which combined the MVA. HIVconsv immunogen with the latency-reversing agent romidepsin in early-ART treated HIV-1 infected individuals, 23% (3/13) of participants showed sustained low-levels of plasma viremia during 32 weeks of a monitored ART pause (MAP). Here, we present a multi-omics analysis to identify compositional and functional gut microbiome patterns associated with HIV-1 control in the BCN02 trial. Viremic controllers during the MAP (controllers) exhibited higher Bacteroidales/Clostridiales ratio and lower microbial gene richness before vaccination and throughout the study intervention when compared to non-controllers. Longitudinal assessment indicated that the gut microbiome of controllers was enriched in pro-inflammatory bacteria and depleted in butyrate-producing bacteria and methanogenic archaea. Functional profiling also showed that metabolic pathways related to fatty acid and lipid biosynthesis were significantly increased in controllers. Fecal metaproteome analyses confirmed that baseline functional differences were mainly driven by Clostridial es. Participants with high baseline Bacteroidales/Clostridiales ratio had increased pre-existing immune activation-related transcripts. The Bacteroidales/Clostridiales ratio as well as host immune-activation signatures inversely correlated with HIV-1 reservoir size. The present proof-of-concept study suggests the Bacteroidales/Clostridiales ratio as a novel gut microbiome signature associated with HIV-1 reservoir size and immune-mediated viral control after ART interruption. The online version contains supplementary material available at 10. 1186/s40168-022-01247-6. |
| Ayudas: | Ministerio de Economía y Competitividad PI16/01421 Ministerio de Economía y Competitividad PI15/01188 European Commission. Horizon 2020 847943 European Commission. Horizon 2020 681137 |
| Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Lengua: | Anglès |
| Documento: | Article ; recerca ; Versió publicada |
| Materia: | HIV-1 post-treatment control ; Gut microbiome ; Therapeutic HIV-1 vaccine ; Viral reservoir size ; Microbiome-based predictive biomarker |
| Publicado en: | Microbiome, Vol. 10 (april 2022) , ISSN 2049-2618 |
